Comparison of the Efficacy of Pericapsular Nerve Group Block Alone Versus Pericapsular Nerve Group Block Combined With Superior Cluneal and Superior Gluteal Nerve Blocks in Patients Undergoing Hip Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: 15 ml Bupivacaine Hcl 0.25% injection, 20 mL bupivacaine 0.25% injection.
- Who it may be relevant to
- Registry conditions: Hip Osteoarthritis, Osteonecrosis of the Femoral Head, Avascular Necrosis of Femur Head, Dysplasia of Hip Joint. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparison of the Efficacy of Pericapsular Nerve Group Block Alone Versus Pericapsular Nerve Group Block Combined With Superior Cluneal and Superior Gluteal Nerve Blocks in Patients Undergoing Hip Surgery: A Prospective Randomized Clinical Study
Overview
In the clinic, total hip arthroplasty is a frequently performed surgical procedure that often results in moderate to severe postoperative pain. Multimodal analgesia approaches are commonly preferred for managing this pain, and in recent years, nerve blocks targeting pelvic innervation have become increasingly prominent. Among these, the Pericapsular Nerve Group (PENG) block has gained attention for providing effective analgesia by targeting the nerves responsible for the anterior innervation of the hip capsule. However, when used alone, the PENG block may be insufficient for controlling posterior hip pain and may not provide complete analgesia. In this context, adding blocks targeting the superior cluneal nerve and the superior gluteal nerve-both of which contribute to the sensory innervation of the posterior hip region-has been proposed to enhance the analgesic effect when combined with the PENG block. Superior cluneal and superior gluteal nerve blocks have recently been described in anatomical and clinical studies, and by affecting the structures contributing sensory input to the posterior hip capsule, they hold significant potential for improving pain management. In this study, the investigators aimed to evaluate the contribution of superior cluneal and superior gluteal nerve blocks, when added to the PENG block, to perioperative analgesia in patients undergoing total hip arthroplasty. The investigators sought to comparatively investigate whether this combination offers superior outcomes compared with the PENG block alone. It was hypothesized that combined nerve blocks may provide similar or improved recovery scores, lower pain scores, reduced opioid consumption, and enhanced analgesic efficacy without affecting the degree of motor blockade.
Interventions
- Drug 15 ml Bupivacaine Hcl 0.25% injection
For PENG Block, 15 mL of 0.25% bupivacaine will be administered. - Drug 20 mL bupivacaine 0.25% injection
After performing PENG; 10 mL of 0.25% bupivacaine will be administered for each superior cluneal nerve block and superior gluteal nerve block
Primary outcome measures
- QoR-15 (Quality of Recovery-15) questionnaire [Time frame: 24th and 48th postoperative hour]
Secondary outcome measures (4)
- Quadriceps Motor Block Assessment [Time frame: It will be assessed at the 4th, 8th, 12th, and 24th postoperative hours.]
- Motor Block Assessment at the Tibialis Anterior Muscle for the Sciatic Nerve [Time frame: It will be assessed at the 4th, 8th, 12th, and 24th postoperative hours.]
- Fentanyl consumption [Time frame: The first 24 postoperative hours]
- VAS pain scores [Time frame: The first 24 postoperative hours]
Eligibility criteria
Inclusion criteria
- Voluntary participation in the study
- Age between 18 and 80 years
- ASA physical status I, II, or III
- Male or female patients
Exclusion criteria
- Refusal to participate in the study
- Allergy to the medications to be used
- History of severe cardiac, renal, or hepatic disease
- Presence of neurological deficits or neuropathy
- History of anticoagulant use
- Previous surgery in the inguinal or suprainguinal region
- Pregnancy
- Chronic opioid use at home
- History of spinal surgery
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Turkey (Türkiye) · 1 center
- Ataturk University — Erzurum
Identifiers
NCT: NCT07255768 · PENGHip